Reprogramming the Tumor Immune Microenvironment Through Activatable Photothermal Therapy and GSH depletion Using Liposomal Gold Nanocages to Potentiate Anti‐Metastatic Immunotherapy DOI
Jiayi Li,

Kaifan Zheng,

Luping Lin

и другие.

Small, Год журнала: 2024, Номер unknown

Опубликована: Окт. 2, 2024

Abstract Cancer immunotherapy offers significant clinical benefits for patients with advanced or metastatic tumors. However, immunotherapeutic efficacy is often hindered by the tumor microenvironment's high redox levels, leading to variable patient outcomes. Herein, a therapeutic liposomal gold nanocage (MGL) innovatively developed based on photo‐triggered hyperthermia and releasable strategy combining glutathione (GSH) depletion remodel immune microenvironment, fostering more robust anti‐tumor response. MGL comprises thermosensitive liposome shell core loaded maleimide. The flexible promotes efficient uptake cancer cells, enabling targeted destruction through photothermal therapy while triggering immunogenic cell death maturation of antigen‐presenting cells. photoactivated release maleimide depletes intracellular GSH, increasing sensitivity oxidative stress thermal damage. Conversely, GSH reduction also diminishes immunosuppressive activity, enhances antigen presentation, activates T Moreover, decreases elevated levels heat shock proteins in further their hyperthermia. In summary, elicited systemic antitumor response depletion, facilitating an effective that reprograms microenvironment significantly inhibits primary This approach demonstrates considerable translational potential applicability.

Язык: Английский

Responsive biomaterials: optimizing control of cancer immunotherapy DOI
Lulu Xue, Ajay S. Thatte, David Mai

и другие.

Nature Reviews Materials, Год журнала: 2023, Номер 9(2), С. 100 - 118

Опубликована: Дек. 22, 2023

Язык: Английский

Процитировано

59
Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells DOI
Nimeet Desai, Uzma Hasan,

K. Jeyashree

и другие.

Acta Biomaterialia, Год журнала: 2023, Номер 161, С. 1 - 36

Опубликована: Март 10, 2023

Язык: Английский

Процитировано

25
Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies In Situ Tumor Vaccination for Boosting Antitumor Immunity DOI
Xiaoyu Xu,

Jinling Zheng,

Na Liang

и другие.

ACS Nano, Год журнала: 2024, Номер 18(13), С. 9413 - 9430

Опубликована: Март 24, 2024

Personalized in situ tumor vaccination is a promising immunotherapeutic modality. Currently, seeking immunogenic cell death (ICD) to generate vaccines still mired by insufficient immunogenicity and an entrenched immunosuppressive microenvironment (TME). Herein, series of tetrazine-functionalized ruthenium(II) sonosensitizers have been designed screened for establishing bioorthogonal-activated vaccine via oncolytic pyroptosis induction. Based on nanodelivery-augmented bioorthogonal metabolic glycoengineering, the original selectively remolded introduce artificial target bicycle [6.1.0] nonyne (BCN) into membrane. Through specific ligation with intratumoral BCN receptors, can realize precise membrane-anchoring synchronous click-activation desired sites. Upon ultrasound (US) irradiation, activated intensively disrupt membrane dual type I/II reactive oxygen species (ROS) generation high-efficiency sonodynamic therapy (SDT). More importantly, severe damage eminently evoke maximize reverse TME, ultimately eliciting powerful durable systemic antitumor immunity. The US-triggered certified effectively inhibit growths primary distant tumors, suppress metastasis recurrence "cold" models. This bioorthogonal-driven tumor-specific induction strategy has great potential development robust vaccines.

Язык: Английский

Процитировано

17
Components, Formulations, Deliveries, and Combinations of Tumor Vaccines DOI
Tengfei Liu,

Wenyan Yao,

Wenyu Sun

и другие.

ACS Nano, Год журнала: 2024, Номер 18(29), С. 18801 - 18833

Опубликована: Июль 9, 2024

Tumor vaccines, an important part of immunotherapy, prevent cancer or kill existing tumor cells by activating restoring the body's own immune system. Currently, various formulations vaccines have been developed, including cell membrane DNA mRNA polypeptide virus-vectored and tumor-in-situ vaccines. There are also multiple delivery systems for such as liposomes, vesicles, viruses, exosomes, emulsions. In addition, to decrease risk escape tolerance that may exist with a single vaccine, combination therapy radiotherapy, chemotherapy, checkpoint inhibitors, cytokines, CAR-T therapy, photoimmunotherapy is effective strategy. Given critical role in here, we look back history discuss antigens, adjuvants, formulations, systems, mechanisms, future directions

Язык: Английский

Процитировано

17
Engineered Bacteriophage-Based In Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity DOI
Lei Lei,

Jiayao Yan,

Kai Xin

и другие.

ACS Nano, Год журнала: 2024, Номер 18(19), С. 12194 - 12209

Опубликована: Май 1, 2024

In situ vaccines (ISVs) utilize the localized delivery of chemotherapeutic agents or radiotherapy to stimulate release endogenous antigens from tumors, thereby eliciting systemic and persistent immune activation. Recently, a bioinspired ISV strategy has attracted tremendous attention due its features such as an adjuvant effect genetic plasticity. M13 bacteriophages are natural nanomaterials with intrinsic immunogenicity, flexibility, cost-effectiveness for large-scale production, demonstrating potential application in cancer vaccines. this study, we propose based on engineered bacteriophage targeting CD40 (M13CD40) dendritic cell (DC)-targeted stimulation, named H-GM-M13CD40. We induce immunogenic death tumor through local (S)-10-hydroxycamptothecin (HCPT), followed by intratumoral injection granulocyte-macrophage colony stimulating factor (GM-CSF) M13CD40 enhance DC recruitment demonstrate that can result significant accumulation activation DCs at site, reversing immunosuppressive microenvironment. addition, H-GM-M13CD40 synergize PD-1 blockade abscopal effects cold models. Overall, our study verifies immunogenicity provides proof concept phage function ISVs.

Язык: Английский

Процитировано

16
Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle DOI
Zhenyu Wang, Tingting You,

Qianyi Su

и другие.

Advanced Materials, Год журнала: 2023, Номер 35(52)

Опубликована: Ноя. 11, 2023

The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address single key aspect to enhance anti-tumor immunity. In the present study, nanoplatform (Fe3 O4 @IR820@CpG)-based immunotherapy strategy that targets multiple steps cancer-immunity cycle is developed: 1) promotes release tumor-derived proteins (TDPs), including tumor-associated antigens and pro-immunostimulatory factors), addition direct killing effect, by photothermal (PTT) photodynamic therapy (PDT); 2) captures released TDPs delivers them, together with CpG (a Toll-like receptor 9 agonist) antigen-presenting cells (APCs) promote antigen presentation T cell activation; 3) enhances tumor-killing ability combining anti-programmed death ligand 1 antibody (α-PD-L1), which collectively advances outstanding effects on colorectal, liver breast cancers. broad-spectrum activity Fe3 @IR820@CpG α-PD-L1 demonstrates optimally manipulating anti-cancer immunity not singly but as group provides promising clinical strategies.

Язык: Английский

Процитировано

21
Adoptive T cell therapy for ovarian cancer DOI
Sarah B. Gitto, Chibuike Ihewulezi, Daniel J. Powell

и другие.

Gynecologic Oncology, Год журнала: 2024, Номер 186, С. 77 - 84

Опубликована: Апрель 10, 2024

Язык: Английский

Процитировано

9
Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments DOI Creative Commons
Konstantinos Avgoustakis, Athina Angelopoulou

Pharmaceutics, Год журнала: 2024, Номер 16(2), С. 179 - 179

Опубликована: Янв. 26, 2024

Solid tumors are composed of a highly complex and heterogenic microenvironment, with increasing metabolic status. This environment plays crucial role in the clinical therapeutic outcome conventional treatments innovative antitumor nanomedicines. Scientists have devoted great efforts to conquering challenges tumor microenvironment (TME), respect effective drug accumulation activity at site. The main focus is overcome obstacles abnormal vasculature, dense stroma, extracellular matrix, hypoxia, pH gradient acidosis. In this endeavor, nanomedicines that targeting distinct features TME flourished; these aim increase site specificity achieve deep penetration. Recently, research focused on immune reprograming order promote suppression cancer stem cells prevention metastasis. Thereby, several nanomedicine therapeutics which shown promise preclinical studies entered trials or already practice. Various novel strategies were employed trials. Among them, based biomaterials show improving efficacy, reducing side effects, promoting synergistic for responsive targeting. review, we mechanisms response solid tumors. We describe take advantage biomaterials’ properties exploit posed by TME. development such systems has significantly advanced application combinational therapies immunotherapies improved anticancer effectiveness.

Язык: Английский

Процитировано

8
Nanotechnology-based in situ cancer vaccines: Mechanisms, design, and recent advances DOI

Gaoli Niu,

Hong Wang, Yanhong Zhai

и другие.

Nano Today, Год журнала: 2024, Номер 56, С. 102286 - 102286

Опубликована: Май 6, 2024

Язык: Английский

Процитировано

8
Enhancing homology-directed repair efficiency with HDR-boosting modular ssDNA donor DOI Creative Commons
Ying-Ying Jin, Peng Zhang, Lele Liu

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Авг. 9, 2024

Despite the potential of small molecules and recombinant proteins to enhance efficiency homology-directed repair (HDR), single-stranded DNA (ssDNA) donors, as currently designed chemically modified, remain suboptimal for precise gene editing. Here, we screen biased ssDNA binding sequences repair-related engineer RAD51-preferred into HDR-boosting modules donors. Donors with these exhibit an augmented affinity RAD51, thereby enhancing HDR across various genomic loci cell types when cooperated Cas9, nCas9, Cas12a. By combining inhibitor non-homologous end joining (NHEJ) or HDRobust strategy, modular donors achieve up 90.03% (median 74.81%) efficiency. The targeting endogenous protein enable a chemical modification-free strategy improve efficacy Single-stranded using current design parameters inefficient authors types.

Язык: Английский

Процитировано

8